GSA Capital Partners LLP Buys New Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

GSA Capital Partners LLP bought a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) in the third quarter, HoldingsChannel reports. The institutional investor bought 11,047 shares of the medical instruments supplier’s stock, valued at approximately $30,000.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Harvard Bioscience by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after acquiring an additional 49,576 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in Harvard Bioscience during the first quarter valued at $54,000. Assenagon Asset Management S.A. grew its holdings in Harvard Bioscience by 193.9% during the second quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after purchasing an additional 150,218 shares during the period. Riverwater Partners LLC increased its position in Harvard Bioscience by 13.7% in the second quarter. Riverwater Partners LLC now owns 105,977 shares of the medical instruments supplier’s stock worth $302,000 after buying an additional 12,780 shares in the last quarter. Finally, Pasadena Private Wealth LLC raised its stake in shares of Harvard Bioscience by 14.8% in the second quarter. Pasadena Private Wealth LLC now owns 198,039 shares of the medical instruments supplier’s stock worth $564,000 after buying an additional 25,554 shares during the period. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Trading Down 1.3 %

Shares of NASDAQ:HBIO opened at $2.24 on Tuesday. The stock has a 50 day moving average of $2.45 and a 200 day moving average of $2.82. The company has a market cap of $97.71 million, a PE ratio of -6.79 and a beta of 1.31. Harvard Bioscience, Inc. has a 12-month low of $1.99 and a 12-month high of $5.56. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.